| Bioactivity | EPZ032597 is a selective and noncompetitive SET and MYND domain-containing protein 2 (SMYD2) inhibitor with an IC50 value of 16 nM. EPZ032597 is promising for research of pancreatic ductal adenocarcinoma[1][2]. |
| CAS | 1887193-58-9 |
| Formula | C20H23N7O |
| Molar Mass | 377.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Alshammari E, et al. Mechanistic and functional extrapolation of SET and MYND domain-containing protein 2 to pancreatic cancer. World J Gastroenterol. 2022 Aug 7;28(29):3753-3766. [2]. Thomenius MJ, et al. Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLoS One. 2018 Jun 1;13(6):e0197372. |
EPZ032597
CAS: 1887193-58-9 F: C20H23N7O W: 377.44
EPZ032597 is a selective and noncompetitive SET and MYND domain-containing protein 2 (SMYD2) inhibitor with an IC50 valu
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.